Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I'm holding my shares. Volume is too small for flipping and it was hard getting the shares I managed to pick up :)
Nephros Receives 510k Approval to Market Additional Ultrafiltration Products
Nephros, Inc. (OTC Bulletin Board: NEPH), a medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purification, today announced that the Company has received 510k clearance from the U.S. Food and Drug Administration to market its MSU and SSU ultrafilters to filter out biological contaminants from water and bicarbonate solution used in hemodialysis procedures.
"Nephros is pleased to have received clearance from the FDA to market the MSU and SSU for hemodialysis applications," said Dr. Paul Mieyal, Acting CEO of Nephros, Inc. "The MSU and SSU represent extensions of the Nephros ultrafiltration product line and enable Nephros products to address a wider range of fluid flow requirements."
About Nephros Ultrafiltration Products
The Nephros DSU, MSU, and SSU are FDA cleared devices for the filtration of biological contaminants from water and bicarbonate concentrate used in hemodialysis procedures. Within the U.S., there are approximately 4,500 clinics providing over 50 million dialysis treatments to 350,000 patients annually. To perform hemodialysis, ultrapure water is crucial to the production of dialysate. Dialysis clinics have water purification systems; however, microbial contaminants can originate from the water treatment system, the water distribution loop, or the dialysate concentrates. Nephros ultrafilters filter out substances down to the 0.005 micron level and address dialysate contamination at crucial points: after the reverse osmosis module and at the dialysis machine entrance from the water distribution loop. Nephros ultrafilters can be used as the last step in the water purification process to ensure that ultrapure water is used for dialysis procedures. Regular use of Nephros ultrafilters offers an affordable safety measure when utilized with modern water treatment systems and optimally maintained hemodialysis machines. Recent data have shown that the Nephros DSU, when used as part of the water purification system for dialysis systems, may reduce the required dosage of erythropoietin stimulating agents, which we believe will provide a unique benefit to patients.
About Nephros, Inc.
Nephros, Inc., headquartered in River Edge, New Jersey, is a medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purification.
The Nephros hemodiafiltration (HDF) system is designed to improve the quality of life for the End-Stage Renal Disease (ESRD) patient while addressing the critical financial and clinical needs of the care provider. ESRD is a disease state characterized by the irreversible loss of kidney function. The Nephros HDF system removes a range of harmful substances more effectively, and with greater capacity, than existing ESRD treatment methods, particularly with respect to substances known collectively as "middle molecules." These molecules have been found to contribute to such conditions as dialysis-related amyloidosis, carpal tunnel syndrome, degenerative bone disease and, ultimately, mortality in the ESRD patient.
The Nephros Dual Stage Ultrafilter (DSU) is the basis for the Nephros line of water filtration products, which includes the MSU and SSU ultrafilters. The patented dual stage cold sterilization ultrafilter has the capability to filter out bacteria and, due to its exceptional filtration levels, filter out many viruses, parasites and biotoxins. Nephros' DSU ultrafilters are being evaluated at several major U.S. medical centers for infection control. Nephros ultrafilter technology has also been selected for further development by the U.S. Marine Corps for purification of drinking water by soldiers in the field.
For more information about Nephros, please visit the company's website at www.nephros.com.
KNDI new HOD
Kandi Technologies Set to Be Big Winner in International Electric Car Market
http://seekingalpha.com/article/280460-kandi-technologies-set-to-be-big-winner-in-international-electric-car-market
Keeping in this level while someone big loads up, in my opinion..or maybe MS still adding to the new position....holding TLB!
KNDI breaking $3
Kandi Technologies Set to Be Big Winner in International Electric Car Market
http://seekingalpha.com/article/280460-kandi-technologies-set-to-be-big-winner-in-international-electric-car-market
KNDI broke $3
Kandi Technologies Set to Be Big Winner in International Electric Car Market
http://seekingalpha.com/article/280460-kandi-technologies-set-to-be-big-winner-in-international-electric-car-market
KNDI on watch, low float
KNDI on watch 2.85
Kandi Technologies Set to Be Big Winner in International Electric Car Market
http://seekingalpha.com/article/280460-kandi-technologies-set-to-be-big-winner-in-international-electric-car-market
Nice buy
What stock are you talking about? TLB?
Nice, also trading this one, SNOFF runningggg
Up 14% today, nice!
There was no particular news that should have caused troubled Puerto Rican banker Doral Financial to tumble last week (though it updated its prospectus in the middle of the free fall), but the markets shaved off nearly a quarter of its value nonetheless.
Earlier this year, Doral bid for rival First Bancorp (NYSE: FBP ) ; although it was rejected, it apparently remains an open offer. But there's also talk that hedge funds would like to make a bid for both banks and consolidate them to create a more financially stable institution. It would create a bank with 81 branches and $23.6 billion in combined assets, putting it on par with Popular Inc. (Nasdaq: BPOP ) , which has 96 branches and $29.5 billion in assets.
EK getting dumped. Earnings next week
You're welcome. Nice low floater, KNDI could be one to watch for a while for trades, considering the news.
KNDI up 29% on news
KNDI now up 34% 2.66
KNDI news
http://www.marketwatch.com/story/kandi-technologies-board-authorizes-5-million-share-repurchase-2011-07-19?reflink=MW_news_stmp
"We believe our recent electric vehicle partnerships and 'Express Change' technology, coupled with our legacy off-road vehicle success, indicate a higher value for Kandi than is currently reflected in our share price."
KNDI news
http://www.marketwatch.com/story/kandi-technologies-board-authorizes-5-million-share-repurchase-2011-07-19?reflink=MW_news_stmp
"We believe our recent electric vehicle partnerships and 'Express Change' technology, coupled with our legacy off-road vehicle success, indicate a higher value for Kandi than is currently reflected in our share price."
KNDI news
http://www.marketwatch.com/story/kandi-technologies-board-authorizes-5-million-share-repurchase-2011-07-19?reflink=MW_news_stmp
"We believe our recent electric vehicle partnerships and 'Express Change' technology, coupled with our legacy off-road vehicle success, indicate a higher value for Kandi than is currently reflected in our share price."
KNDI - low floater, with news of share repurchase
http://www.marketwatch.com/story/kandi-technologies-board-authorizes-5-million-share-repurchase-2011-07-19?reflink=MW_news_stmp
EK news
http://www.reuters.com/article/2011/07/18/apple-kodak-patent-idUSN1E76H1SQ20110718
2.65 premarket, currently up 5%
Morgan Stanley Capital Services LLC (NYSE:MS) has opened up a new position in The Talbots Inc. (NYSE: TLB) worth $12.14 million, according to an SEC filing.
The New York firm said it owned 3.83 million shares, representing a 5.4 percent stake, in the Hingham, Mass.-based specialty retailer. The stake's value is based on the stock's closing price of $3.17 per share on July 15.
The Talbots, founded in 1947 by Nancy and Rudolph Talbots, is a specialty retailer and direct marketer of women's apparel, shoes and accessories. It operates 568 stores in 46 states and Canada.
The Talbots is led by CEO Trudy F. Sullivan, who previously held senior positions at Liz Claiborne Inc.
What is Substantial Equivalence?
explained: http://www.fda.gov/medicaldevices/deviceregulationandguidance/howtomarketyourdevice/premarketsubmissions/premarketnotification510k/default.htm#se
To acquire clearance to market a device using the 510(k) pathway, the submitter of the 510(k) must show that the medical device is "substantially equivalent" to a device that is already legally marketed for the same use.
Device Classification Name Subsystem, Water Purification
510(K) Number K110285
Device Name NEPHROS DSU FILTER, NEPHROS MSU FILTER, NEPHROS SSU FILTER
Applicant
NEPHROS, INC.
41 Grand Ave.
River Edge, NJ 07661
Contact James Summerton
Regulation Number 876.5665
Classification Product Code
FIP
Date Received 03/03/2011
Decision Date 07/14/2011
Decision Substantially Equivalent (SE)
Classification Advisory Committee Gastroenterology/Urology
Review Advisory Committee Gastroenterology/Urology
Type Special
Reviewed By Third Party No
Expedited Review No
* Morgan Stanley reports 5.4% passive stake in Talbots Inc as of July 8, 2011 - SEC filing today
TLB
DRL - close to support 1.93
What happened with GBOE?
I've not watched VRAL for a long time, and noticed that they may be wanting to pick up steam with IR. Could be good for a trade, but want to watch L2 for a while. Don't know if there is a risk of dilution here?
bid/ask spread is closing slightly, unfortunately very little volume, this stock requires a lot of patience for the end of year
Any life here?
SAN MARINO, Calif., July 14, 2011 /PRNewswire/ -- Viral Genetics, Inc. (Pinksheets: VRAL) will be holding a webcast presentation at 4:30PM Eastern Time on August 3, 2011 to discuss the company's recent results of operations and other developments in connection with its March 31, 2011 Quarterly Report and 2010 Annual Report. A link to register for the webcast will be provided in a press release prior to the presentation and will also be made available on the Company's website. Individuals are encouraged to submit questions about the company to info@viralgenetics.com for consideration for inclusion in the Q&A session following the presentation by Company President, Haig Keledjian.
The company intends to hold regular webcast presentations to discuss operations moving forward as part of an enhanced overall communications strategy. The timing of any additional presentations may differ from quarterly and annual report filing dates, depending on the pace and timing of new developments.
As part of this effort, the company has also recently added several features to its website at www.viralgenetics.com and other communications tools:
Email Signup - Individuals can now provide their name and email address on the company's website and be provided with press releases, filings, scientific publications, presentation dates, and other information on an ongoing basis.
Corporate Presentation – a PowerPoint presentation is available for download at http://www.viralgenetics.com/VG-IVSTR-Presentation-Q2-11.pptx.zip that discusses the company's pharmaceutical research programs, its VG Energy subsidiary's biofuel and agri-tech product development, future milestones, and other company information.
Corporate Fact Sheet – this 1-page summary of the company's current plans and milestones will be updated at least quarterly, and is also available to download at http://www.viralgenetics.com/ViralGenetics-FactSheet-Q2-11.pdf.
The 2010 and first quarter reports, including unaudited consolidated financial statements for the year ending December 31, 2010 and the three months ended March 31, 2011, are available at http://www.otcmarkets.com/stock/VRAL/financials.
"With so many projects moving forward simultaneously, it is more important than ever to maintain a regular flow of information to our shareholders and stakeholders," said Viral Genetics' President, Haig Keledjian.
About Viral Genetics, Inc.
San Marino, California-based Viral Genetics discovers drug therapies from two platform technologies based on over 60 patents: Metabolic Disruption (MDT) and Targeted Peptides (TPT). Founded in 1994, the biotech company is researching treatments for HIV/AIDS, Lyme Disease, Strep, Staph and drug resistant cancer. A majority-owned subsidiary, VG Energy (www.vgenergy.net), is dedicated to exploring biofuel and agricultural applications for the MDT platform. For more information, visit www.viralgenetics.com.
TLB bouncing off low 3's, heavy short interest, buyout rumors circulating, on watch
DRL recent pullback from 2.60s, 2.01 x 2.02, moves quickly
DRL looking at 1.95 to 2.0's for entry on pullback
Added some on the dip, overall market volatility, but DRL can move faast!
DRL dipping... hmm buy opp?
That is good news...looks like some have been trying to accumulate, but shares are getting really scarce on NEPH!!!
GL
Now we have cash that at our current burn rate will keep nephros afloat beyond 2016.
2.64! DRL